134 related articles for article (PubMed ID: 38433342)
1. mTor-inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy.
Kreienbaum H; Stiller B; Kubicki R; Bobrowski A; Kroll J; Fleck T
Pediatr Transplant; 2024 Mar; 28(2):e14698. PubMed ID: 38433342
[TBL] [Abstract][Full Text] [Related]
2. Pediatric heart transplantation: 23-year single-center experience.
Huebler M; Schubert S; Lehmkuhl HB; Weng Y; Miera O; Alexi-Meskishvili V; Berger F; Hetzer R
Eur J Cardiothorac Surg; 2011 May; 39(5):e83-9. PubMed ID: 21354807
[TBL] [Abstract][Full Text] [Related]
3. Conversion to everolimus in pediatric heart transplant recipients is a safe treatment option with an impact on cardiac allograft vasculopathy and renal function.
Grimm K; Lehner A; Fernandez Rodriguez S; Orban M; Fischer M; Rosenthal LL; Jakob A; Haas NA; Dalla Pozza R; Kozlik-Feldmann R; Ulrich SM
Clin Transplant; 2021 Mar; 35(3):e14191. PubMed ID: 33315277
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
Arora S; Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Sigurdardottir V; Dellgren G; Erikstad I; Solberg OG; Ueland T; Aukrust P; Gullestad L;
Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
[TBL] [Abstract][Full Text] [Related]
5. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
[TBL] [Abstract][Full Text] [Related]
6. Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients.
Bergh N; Gude E; Bartfay SE; K Andreassen A; Arora S; Dahlberg P; Dellgren G; Gullestad L; Gustafsson F; Karason K; Rådegran G; Bollano E; Andersson B
ESC Heart Fail; 2020 Apr; 7(2):567-576. PubMed ID: 32059083
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
8. Pediatric recipient survival beyond 15 post-heart transplant years: a single-center experience.
Copeland H; Razzouk A; Chinnock R; Deming D; Hasaniya N; Bailey L
Ann Thorac Surg; 2014 Dec; 98(6):2145-50; discussion 2150-1. PubMed ID: 25443019
[TBL] [Abstract][Full Text] [Related]
9. Early aspirin use and the development of cardiac allograft vasculopathy in pediatric heart transplant recipients: A pediatric heart transplant society analysis.
D'Addese L; Cantor RS; Koehl D; Reardon L; Ameduri R; Bock M; Morrison A; White S; Wisotzkey B; Kirklin JK; Godown J
J Heart Lung Transplant; 2023 Jan; 42(1):115-123. PubMed ID: 36328858
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
Fine NM; Kushwaha SS
Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
[TBL] [Abstract][Full Text] [Related]
11. Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression.
Norum HM; Michelsen AE; Lekva T; Arora S; Otterdal K; Olsen MB; Kong XY; Gude E; Andreassen AK; Solbu D; Karason K; Dellgren G; Gullestad L; Aukrust P; Ueland T
Am J Transplant; 2019 Apr; 19(4):1050-1060. PubMed ID: 30312541
[TBL] [Abstract][Full Text] [Related]
12. Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all?
Gude E; Gullestad L; Andreassen AK
Curr Opin Organ Transplant; 2017 Jun; 22(3):198-206. PubMed ID: 28463861
[TBL] [Abstract][Full Text] [Related]
13. Heart transplantation: 25 years' single-centre experience.
Bruschi G; Colombo T; Oliva F; Botta L; Morici N; Cannata A; Vittori C; Turazza F; Garascia A; Pedrazzini G; Frigerio M; Martinelli L
J Cardiovasc Med (Hagerstown); 2013 Sep; 14(9):637-47. PubMed ID: 23340045
[TBL] [Abstract][Full Text] [Related]
14. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
Mirza K; Gustafsson F; Gullestad L; Arora S; Andersen C
Transpl Immunol; 2016 Sep; 38():75-7. PubMed ID: 27260644
[TBL] [Abstract][Full Text] [Related]
15. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
[TBL] [Abstract][Full Text] [Related]
16. Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.
Watanabe T; Seguchi O; Nishimura K; Fujita T; Murata Y; Yanase M; Sato T; Sunami H; Nakajima S; Hisamatsu E; Sato T; Kuroda K; Hieda M; Wada K; Hata H; Ishibashi-Ueda H; Miyamoto Y; Fukushima N; Kobayashi J; Nakatani T
Int J Cardiol; 2016 Jan; 203():307-14. PubMed ID: 26523360
[TBL] [Abstract][Full Text] [Related]
17. Impact of Everolimus Initiation and Corticosteroid Weaning During Acute Phase After Heart Transplantation on Clinical Outcome: Data from the Korean Organ Transplant Registry (KOTRY).
Lee KS; Kim H; Lee SH; Choi DJ; Yoon M; Jeon ES; Choi JO; Kang J; Lee HY; Jung SH; Oh J; Kang SM; Lee SY; Ju MH; Kim JJ; Kim MS; Cho HJ
Transpl Int; 2024; 37():11878. PubMed ID: 38644935
[TBL] [Abstract][Full Text] [Related]
18. Freedom from graft vessel disease in heart and combined heart- and kidney-transplanted patients treated with tacrolimus-based immunosuppression.
Groetzner J; Kaczmarek I; Mueller M; Huber S; Deutsch A; Daebritz S; Arbogast H; Meiser B; Reichart B
J Heart Lung Transplant; 2005 Nov; 24(11):1787-92. PubMed ID: 16297783
[TBL] [Abstract][Full Text] [Related]
19. Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients-a SCHEDULE trial substudy.
Nelson LM; Andreassen AK; Arora S; Andersson B; Gude E; Eiskjaer H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
Transpl Int; 2020 May; 33(5):517-528. PubMed ID: 31958178
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of third heart transplants in pediatric and young adult patients: analysis of the United Network for Organ Sharing database.
Friedland-Little JM; Gajarski RJ; Yu S; Donohue JE; Zamberlan MC; Schumacher KR
J Heart Lung Transplant; 2014 Sep; 33(9):917-23. PubMed ID: 24861821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
